RaySearch RayStation Fallback (FB) planning module can generate an equivalent backup radiotherapy treatment plan facilitating treatment on other linear accelerators. FB plans were generated from the RayStation FB module by simulating the original plan target and organ at risk (OAR) dose distribution and delivered in various backup linear accelerators. In this study, helical tomotherapy (HT) backup plans used in Varian TrueBeam linear accelerator were generated with the RayStation FB module. About 30 patients, 10 with lung cancer, 10 with head and neck (HN) cancer, and 10 with prostate cancer, who were treated with HT, were included in this study. Intensity-modulated radiotherapy Fallback plans (FB-IMRT) were generated for all patients, and three-dimensional conformal radiotherapy Fallback plans (FB-3D) were only generated for lung cancer patients. For 3D lung cancer plans, only the PTV R 95 was statistically comparable between HT and FB-3D plans, PTV D mean was higher, and CI and HI were worse compared to HT plans. The FB plans using a TrueBeam linear accelerator generally offer better OAR sparing compared to HT plans for all the patients. In this study, all cases of FB-IMRT plans and 9/10 cases of FB-3D plans were clinically acceptable without further modification and optimization once the FB plans were generated. However, the statistical differences between HT and FB-IMRT/3D plans might not be of any clinically significant.
Generally, treatment planning software system (TPS) is an integrated software package that allows the target and organs at risk (OAR) definitions, management of treatment plan, plan optimization, and delivery quality assurance (DQA). It also includes the DICOM import and export and data management system application software for archiving and management of patient data. TPS such as Eclipse (Varian Medical Systems, Palo Alto, CA, USA), Tomotherapy (Accuracy Inc, Sunnyvale, CA, USA), Pinnacle (Philips Healthcare, Andover, MA, USA), RayStation (RaySearch Medical Laboratories, Stockholm, Sweden) have different dose calculation engines as well as other characteristics that are unique to each system. Furthermore, each TPS needs to be commissioned using beam data from the linear accelerator to be used for patient treatment delivery. For example, a treatment plan generated from TPS that is commissioned to Varian Clinac iX linear accelerator could not be directly used to treat with Varian TrueBeam linear accelerator. In summary, there is no easy way to transfer patient treatment plans between different TPSs without repeating a significant amount of work.
Due to the lack of interchangeability among TPSs, there is a need to develop a method that can automatically transfer patient plans from one treatment unit/TPS to another treatment unit/TPS. This is especially useful for treatment centers that have multiple treatment units and TPSs that want to switch patients due to, for example, scheduling conflicts and machine down time.
Recently, RayStation TPS developed several advanced features to generate backup treatment plans. 1 RayStation TPS has a module named Fallback (FB) which uses a dose mimicking technique to create a backup plan, enabling a patient to be treated on another machine, possibly with a different treatment technique. At present and to our knowledge, there is no dosimetric evaluation published in the literature for the RayStation FB module. The purpose of this study was to provide insight into the use of the RayStation FB module for generating 3D and IMRT FB backup plans (FB-IMRT and FB-3D plans) that can be delivered at different treatment machines.
Helical tomotherapy (Accuracy Inc, Sunnyvale, CA, USA) is a treatment machine that is heavily used in our clinic; we select the angle-specific protocol plans (i.e., six field, seven field, or nine field), target position-specific protocol plans (i.e., head first or feet first).
The protocol plans also can be very specific used as a patient-specific protocol plan. A more specific protocol plan will result in a much higher degree of correspondence between the original HT plan and the resultant FB plan; however, a great deal of time and effort will be needed to generate these protocol plans.
2.C | Fallback plan creation
In this study, lung and HN IMRT FB plans shared the same single gets are given a weighting factor equal to a user-defined target priority (Target/OARs ratios). In this study, the dose mimicking target/ OAR optimization weighting factor was set to 100.00 which means the importance of the optimization goal for target over OARs is 100.
Usually, the higher the ratio, the more importance for the target dose simulation and the lower the ratio, the more importance for the OARs dose simulation.
The energies of 6 MV were selected for lung and HN patients and 10 MV was selected for prostate patients. For FB-3D plans, patient-specific individual protocol plans were used. The plan parameters such as gantry, collimator, couch, and wedge angles for the FB-3D plans were determined individually and the final protocols selected were the ones that could best mimic the original HT plans. Dprescription ) where D x% is the dose to x% of the target volume, Paddick's conformity index (CI) 2 , and homogeneity index (HI). CI was defined by the following equation.
Where TV is the target volume, TV PIV is the target volume covered by the prescription isodose volume (PIV), and V PIV is the total prescription isodose volume. HI was defined by the following equa-
Dosimetric data comparison between the FB plan and the original HT plan was performed using Wilcoxon matched-pair signed rank test to clarify the differences in our results. Values of P ≤ 0.05 were considered significant. The median and range of OAR doses for FB-IMRT and HT plans for lung, HN, and prostate patients are listed in Table 2 (a-c). For lung cancer patients, there was no statistically significant difference in cord dose and there were statistically significant difference for all the other OARs (P < 0.05) which received higher doses in HT plans.
For the prostate patients, there were statistically significant differences for all OARs doses which received higher doses in HT plans.
For the HN patients, there was a statistically significant difference for the cord and larynx dose, where cord dose was lower and larynx dose was higher in HT plans compared to FB-IMRT plans and there were no statistically significant differences for all the other OAR doses between FB-IMRT plans and HT plans.
The maximum dose differences for OARs between the FB-IMRT and HT plans were also evaluated and the median maximum dose differences were less than 1Gy for all the OARs in the treatment plan conversion between HT plan to FB-IMRT plans for all the lung, HN, and prostate patients.
The comparison between the FB-3D plan and the original HT plan was performed for lung cancer patients. The median values and ranges for PTV D mean , R 95 , CI, and HI for total nine lung patients (1/10 patients was excluded because of an unacceptable treatment plan) The median values and ranges of OAR doses calculated from the FB-3D plans and HT plans for lung patients were listed in Table 3 We noticed that only the DVH of PTV-66 had an acceptable agreement between FB-IMRT and original HT plans comparing single-target dose simulation (Fig. 6 ) and multitarget dose simulation ( was comparable between HT plans and FB-3D plans, the PTV D mean was higher for FB-3D plans and CI and HI were worse compared to HT plans. These results were expected as HT is an IMRT treatment plan and it is a high-precision technique especially on PTV conformity and homogeneity compared to 3D treatment technique. 7 This study shows that FB-3D plan could be an easy replacement backup plan for those cases where IMRT is not an available option. In addition, the FB-3D plans could be improved in RayStation TPS if needed.
| CONCLUSION S
Helical tomotherapy backup plans used in Varian TrueBeam linear accelerator were generated using RayStation Fallback module and the FB plans and the original HT plans were compared. The Fallback plans were generated based on the preselected protocol plans and no further optimization and modification were performed to improve the FB plan as long as the protocol plan was selected in this study.
All the FB-IMRT plans were acceptable for use in clinic. There were some statistical differences when comparing different types of FB-3D plans were also generated in RayStation TPS for lung cancer patients and it had higher D mean and worse CI and HI compared with the original HT plans in this study. It was noted that FB-3D
plans could fail to simulate doses from the original HT plan and might require more time and effort to create an acceptable plans compared to FB-IMRT plans.
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F I G . 6. Example of DVH calculated from FB-IMRT and HT plans with one PTV target (PTV66 and Target/OARs optimization weighting factor = 100) for one HN patient.
